Quantum Computing (QUBT) Q2 2026 Earnings Call Transcript

Quantum Computing Inc. (QUBT) reported Q2 revenue of $5.6M (vs. $0.061M a year ago), but posted a net loss of $11.8M (loss of $0.05/share). Operating expenses rose 114% to $21.8M, while $13M of interest income helped offset costs; the improved loss was largely due to a smaller non-cash mark-to-market loss on derivative liabilities ($1.7M vs. $28M). The company also completed $180M of cash acquisitions (including Luminar Semiconductor, NuCrypt, and NHanced) and reported $42.5M backlog with revenue mix still 70%–80% government subcontracting, while acknowledging “lumpy” timing on large defense funding.

Analysis

This reads more like a balance-sheet-funded option on commercialization than a clean operating inflection. The real mechanism to watch is conversion quality: government-heavy, long-cycle work can pad backlog without producing the kind of near-term billings that supports a durable re-rate, so the market should discount any “commercial readiness” language until third-party orders recur and acceptance milestones show up in revenue.

The second-order winner is the vertically integrated photonics/foundry stack, not the quantum narrative by itself. If the new packaging capacity is real, QUBT can pull more value into-house and potentially become a niche supplier to defense, telecom, and AI inference customers; but that also raises fixed-cost absorption risk, so utilization matters more than headline capacity. Suppliers that benefit are specialty semiconductor tools/materials vendors; losers are outsourced packaging providers if QUBT actually internalizes more of the chain.

Near term, the catalyst is the promised Dirac-3 update over the next month; that can move the stock for days to weeks if it comes with independently verifiable benchmark data, but the move reverses quickly if the disclosure is only marketing. Over 1-3 months, the key falsifier is another quarter of revenue stuck in low single digits while opex keeps running ahead of sales. Over 6-18 months, the real question is whether acquisitions create a platform business or just a serially diluted story stock.

Contrarian take: the market may be overvaluing the quantum label and underestimating the photonics manufacturing asset, but it is also likely underpricing how lumpy and customer-specific this revenue can be. I would not assume the cash balance eliminates downside; it mainly buys time, and time only helps if management can prove repeatable demand rather than one-off demos.

Key Decisions for Investors

• Avoid initiating fresh long exposure in QUBT until management publishes verifiable Dirac-3 benchmark data or shows two consecutive quarters of sequential revenue growth with backlog conversion.
• On any post-call strength, buy a 1-3 month QUBT put spread as a defined-risk way to express skepticism that the commercialization narrative will translate into near-term numbers; thesis breaks if revenue exits the low-single-digit range or backlog converts faster than expected.
• Pair trade: long IONQ or RGTI versus short QUBT for 1-2 quarters, betting the market rewards clearer commercialization and penalizes the more acquisition-heavy, harder-to-model story; cover if QUBT posts meaningful third-party order flow or margin improvement.
• If you want AI-semiconductor exposure, prefer NVDA or SMH over QUBT; QUBT’s upside is speculative and milestone-driven, while NVDA monetizes actual capex today.